1	TITLE: Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
2	
3	<b>AUTHORS:</b> Yoo Jin Kim, MD MS <sup>1*</sup> , Jana Lovell, MD <sup>2*</sup> , Alaa Diab, MD MPH <sup>2</sup> , Laurence S.
4	Magder, PhD MPH <sup>3</sup> , Daniel Goldman, PhD MCS <sup>4</sup> , Michelle Petri, MD MPH <sup>4</sup> ,
5	Andrea Fava, $MD^{4\square}$ , Luigi Adamo, MD Ph $D^{2\square}$
6	
7	AFFILIATIONS:
8	1. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD
9	2. Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD
10	3. Department of Epidemiology & Public Health, University of Maryland School of Medicine,
11	Baltimore, MD
12	4. Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore,
13	MD
14	* These authors contributed equally to this work
15	□ These authors co-directed this work
16	
17	CORRESPONDING AUTHORS:
18	Dr. Luigi Adamo & Dr. Andrea Fava
19	Division of Cardiovascular Medicine & Rheumatology, Department of Medicine
20	Johns Hopkins University, Baltimore, MD
21	Email: <u>ladamo2@jhmi.edu</u> & <u>afava1@jhmi.edu</u>

### 23 ABSTRACT

- 24 **IMPORTANCE:** Pericarditis is the most common cardiac manifestation of Systemic Lupus
- 25 Erythematosus (SLE) and known to recur among patients. Yet, the prevalence and risk factors of
- 26 recurrent pericarditis in SLE patients are unknown.
- 27 **OBJECTIVE:** Determine the frequency and risk factors for the recurrence of pericarditis in

28 patients with SLE.

- 29 **DESIGN:** Retrospective analysis of a well-characterized, prospective cohort of SLE patients
- 30 enrolled between 1988 and 2023.

**SETTING:** A single-center cohort study of a diverse group of SLE patients treated at a tertiary

- 32 medical center.
- PARTICIPANTS: Patients diagnosed with pericarditis (n=590) among those enrolled in the
  Hopkins Lupus Cohort (n=2931).

MAIN OUTCOME: Re-occurrence of pericarditis. The SELENA revision of the SLE Disease
Activity Index (SLEDAI) was used to define pericarditis. Clinical information was examined for
all follow-up encounters after the first episode of pericarditis. Pericarditis that occurred at least
six weeks after the first recorded episode was defined as "Recurrent".

RESULTS. Of 2931 patients within the cohort, 590 had a history of pericarditis. In 3.4% of patients, the diagnosis of pericarditis was confirmed via electrocardiogram (EKG) or dedicated imaging, with 100% concordance between clinical and data-based diagnoses. During a median follow-up of 7 years (IQR: 3 – 14), 20% (n=120) of patients experienced recurrent pericarditis (recurrence rate ≈ 0.05 per person-year of follow-up). Most patients (51%) experienced only one recurrence, whereas 49% had ≥2 recurrences. In multivariate analysis, predictors of recurrence

45	included younger age ( $\geq 60$ years vs. <40, RR 0.11 (0.04, 0.32), P <.001), treatment with
46	prednisone ( $\geq$ 20 mg vs. 0, RR 1.99 (1.17, 3.40), $P = 0.012$ ), active SLE disease (SLEDAI $\geq$ 3 vs.
47	0, RR 1.55 (1.21, 2.00), P <.001), and time since initial episode (3-10 years vs. <1, RR 0.32
48	(0.20, 0.52), <i>P</i> <.001).
49	CONCLUSION AND RELEVANCE. Recurrence is more likely to occur within one year of the
50	onset of pericarditis, and younger patients and those with uncontrolled disease are at greater risk

51 of recurrence. As in the general population, oral prednisone therapy is associated with a higher

52 chance of recurrence in SLE patients, with a dose-dependent effect. These findings set the basis

53 for future studies to define optimal treatment for recurrent pericarditis in SLE patients and

54 suggest that oral corticosteroids should be avoided when treating pericarditis.

#### 56 **INTRODUCTION**

Pericarditis, defined as inflammation of the serosal sac that surrounds the myocardium, is 57 58 the most common cardiac manifestation of systemic lupus erythematosus (SLE) and noted in about 20% of patients.<sup>1-3</sup> Patients can experience a spectrum of symptoms, ranging from mild 59 60 chest pain exacerbated by lying flat that is improved by leaning forward, to debilitating 61 symptoms of severe chest pain and dyspnea. Importantly, pericarditis is associated with 62 complications that include recurrence, myocarditis, and pericardial effusion. In the general population, pericarditis recurs in approximately 30% of cases.<sup>4</sup> Despite the 63 significant rate of recurrence, the mechanisms predisposing a subset of individuals to recurrence 64 65 remains unclear. Caforio and colleagues demonstrated the presence of serum anti-heart and antiintercalated-disk autoantibodies in patients with recurrent pericarditis.<sup>5</sup> Furthermore, multiple 66 67 clinical trials have demonstrated the efficacy of immunosuppressive agents, such as corticosteroids, in treating recurrent pericarditis, suggesting an immune-mediated mechanism.<sup>5-8</sup> 68 69 Recent pivotal studies further support this hypothesis, particularly implicating interleukin-1, a 70 pro-inflammatory cytokine of the innate immune system, in the pathophysiology of recurrent pericarditis. Inhibitors targeting this pathway have proven effective in treating idiopathic 71 recurrent pericarditis across multiple randomized clinical trials.<sup>7-14</sup> 72

Given the broad immune dysregulation associated with SLE, patients may face greater
risk for recurrence due to possible overlapping immune-mediated mechanisms. However, the rate
of recurrence of pericarditis in SLE patients, its risk factors, and its association with various
treatments have not been characterized. To address this knowledge gap, we analyzed the Hopkins
Lupus Cohort, a large and well-characterized longitudinal cohort of SLE patients.

#### 79 **METHODS**

100

**Patients.** The Hopkins Lupus Cohort is a longitudinal, prospective cohort of patients whose 80 diagnosis of SLE is confirmed before study enrollment.<sup>15</sup> Patient history, laboratory testing, and 81 82 clinical information relevant to the classification of SLE and Systemic Lupus International 83 Collaborating Clinics / American College of Rheumatology Damage Index (SLICC/ACR SDI) are recorded at the time of cohort entry.<sup>16</sup> Cohort patients are followed quarterly at a minimum, 84 85 and clinical information and laboratory testing are updated at subsequent clinical visits. The 86 Hopkins Lupus Cohort is approved yearly by the Institutional Review Board of the Johns Hopkins University School of Medicine. We identified patients who either had a history of 87 pericarditis at the time of cohort entry or were diagnosed with pericarditis during cohort 88 89 participation utilizing the criterion described below. 90 91 **Diagnostic criteria for pericarditis.** Pericarditis was diagnosed using the Safety of Estrogens in Lupus Erythematosus National Assessment – SLE Disease Activity Index (SELENA-SLEDAI).<sup>17</sup> 92 93 One of the following criteria was necessary to be present for the diagnosis of pericarditis: (1) 94 pericardial pain, (2) auscultation of pericardial rub, (3) presence of pericardial effusion on imaging, and (4) electrocardiogram (EKG) confirmation.<sup>17,18</sup> Clinical information was examined 95 96 for all follow-up encounters after the first episode of pericarditis. "Recurrent" pericarditis was 97 defined as pericarditis that occurred at least six weeks after the first recorded episode. Multiple 98 recurrent episodes were identified if pericarditis occurred at least six weeks apart. 99

101 patient's first episode of pericarditis. For those with a history of pericarditis prior to cohort entry,

Statistical analysis. The analysis was based on cohort observations that occurred after the

102 all cohort follow-up encounters were included. Cohort data were reformatted into a data set with 103 one record for each person-month of follow-up and used to calculate the rate of reoccurrence per 104 person-month given various patient characteristics or exposures. For ease of interpretation, rates 105 per person-month were converted to rates per person-year of follow-up. Rate ratios, confidence 106 intervals, and p-values were calculated using pooled logistic regression (a form of discrete 107 survival analysis) as implemented using generalized estimating equations (to account for the fact that some participants experienced more than one recurrence).<sup>19</sup> Analyses were performed using 108 109 SAS 9.4 (SAS Institute, Carey, North Carolina, USA). 110 111 RESULTS 112 Patient characteristics. Among the Hopkins Lupus Cohort (n=2931), 590 patients with a 113 history of pericarditis were included in analysis. Of these 590 patients, 451 (76%) patients 114 experienced their first episode of pericarditis prior to cohort entry, and the remaining 139 115 patients experienced their first episode while in the cohort. The majority of patients were women 116 (n = 535, 91%) and identified as Black (n = 303, 51%) (Table 1). The median duration of cohort 117 follow-up observed following the initial acute pericarditis episode was 6.7 years (IQR: 2.5 – 118 13.6). 119 120 **Overall rate of reoccurrence.** We observed a total of 5277 years of follow-up during which 121 time there were 278 recurrences of pericarditis for a rate of 0.053 per person-year of follow-up

(95% CI 0.047, 0.059). These events occurred in 120 different patients (20%), and 59 (49%) of

123 those patients experienced more than one episode of recurrence.

124

125	Diagnostic criteria for pericarditis. Patients were diagnosed with pericarditis based on the
126	SLEDAI criteria, which required the presence of at least one of the following: pericardial chest
127	pain, pericardial friction rub on auscultation, evidence of effusion, or findings on EKG. Most
128	patients were diagnosed based on symptomatic reports of pericardial chest pain ( $n = 567, 96\%$ ).
129	EKG or imaging studies were performed on a small subset of patients: EKG was conducted in 1
130	(0.2%), while transthoracic echocardiogram (TTE) or computed tomography (CT) imaging
131	findings demonstrated a pericardial effusion in 19 (3%) and 1 (0.2%) patients, respectively.
132	Importantly, when diagnostic data was collected in conjunction with symptomatic reports of
133	chest pain, the clinical diagnosis of pericarditis was confirmed 100% of the time.
134	
135	Risk factors for recurrent pericarditis. Demographic, clinical, serologic, and treatment
136	characteristics were studied in univariate analysis to determine their association with recurrence
137	among patients with pericarditis (Table 2). Sex did not significantly impact recurrence rates.
138	Black race was associated with an increased risk of recurrent pericarditis (RR 1.72 (0.99, 2.97),
139	P = 0.054), and older age was associated with lower rates of recurrent pericarditis (40-49 years
140	[RR 0.58 (0.37, 0.90), $P = 0.016$ ] or 50-59 years [RR 0.25 (0.12, 0.53), $P < .001$ ] vs. 18-39 years).
141	Recurrence was more likely to occur within the first year from onset, after which the likelihood
142	of recurrence decreased (1-3 years vs. <1 RR 0.50 (0.32, 0.79), $P = 0.003$ ).
143	We evaluated the association of SLE disease activity with the risk of recurrence. We
144	found that patients with active lupus (SLEDAI scale score $\geq$ 3) experienced significantly
145	increased rates of recurrence (RR 2.34 (1.65, 3.30), $P < .001$ ). Systemic SLE activity beyond the
146	pericardium was associated with a risk of recurrence. Interestingly, patients with renal
147	involvement, such as proteinuria and nephrotic syndrome, as well as those with pulmonary

148	hypertension, had decreased recurrence rates (Table 2). Hypocomplementemia (C3 and C4) was
149	associated with increased rates of recurrence. However, a statistically significant association was
150	limited to C4 (Normal vs. low C4, RR 0.54 (0.37, 0.78), $P = 0.01$ ) rather than reduced C3
151	(Normal vs. low C3, RR 0.76 (0.52, 1.09), $P = 0.14$ ). Seropositivity for double-stranded DNA
152	(dsDNA) antibodies was associated with increased recurrence (RR 2.05 (1.40, 2.99), $P < .001$ ).
153	Finally, the therapies of SLE patients with recurrent pericarditis were assessed. Treatment
154	with oral prednisone at any dose was associated with increased rates of recurrence. Furthermore,
155	a dose-dependent association with recurrence was observed as the greatest rates of recurrence
156	were observed with the highest daily doses of prednisone ( $\geq 20$ mg) (RR 3.92 (2.31, 6.63), P
157	<.001). The use of hydroxychloroquine and other immunosuppressants did not affect recurrences,
158	and rates of pericarditis were lower after the year 2000. (Table 2).
159	To gain further insights into our findings, we performed a multivariate Cox hazard model
160	incorporating covariates identified as significant in the univariate analyses ( $P < 0.05$ ) ( <u>Table 2</u> ).
161	The model identified younger age (< 40 years), time from first episode (< 1 year), daily
162	prednisone use ( $\geq 20$ mg), and clinically active disease (SLEDAI $\geq 3$ ) as independent predictors
163	of recurrent pericarditis (Figure 1). Other variables that were found to be associated with
164	recurrence in the univariate analyses (low C4, anti-dsDNA, proteinuria, and history of
165	pulmonary hypertension) were not significantly associated with recurrence after adjustment for
166	other variables in the multivariable model.

## 167 **DISCUSSION**

168	In this study, we present a prospective analysis of recurrent pericarditis among SLE
169	patients. The rate of recurrent pericarditis among patients with SLE was 0.05 per year (120/590
170	patients, 20%). We found that whereas clinically active SLE and younger age are predictors of
171	recurrence, systemic involvement beyond the pericardium, such as the renal system (e.g.,
172	nephrotic syndrome and proteinuria) and pulmonary hypertension, may lead to decreased
173	recurrence. Importantly, prednisone use led to an increased risk of disease recurrence. These
174	findings expand our understanding of lupus pericarditis, underscore the need to reconsider using
175	oral prednisone to treat SLE flares involving the pericardium and identify the need for further
176	investigation of treatments for lupus pericarditis.
177	SLE is a complex disease characterized by broad immune dysregulation that is
178	considered the result of autoantibody production from irregularly activated and differentiated B
179	lymphocytes and abnormal interferon activity. <sup>20</sup> Similarly, the pathogenesis of recurrent
180	pericarditis in the general population has been presumed to be immune-mediated. <sup>8</sup> Given the
181	increased potential for auto-immunity among patients with SLE, we hypothesized that patients
182	with SLE might experience an increased rate of recurrence following an acute episode of
183	pericarditis. Surprisingly, we found that the rate of pericarditis recurrence among patients with
184	SLE (20%) was lower than that reported in the general population (~33%). <sup>4,18</sup>
185	Prior studies have examined risk factors for acute pericarditis among patients with SLE.
186	Ryu et al. reported predictors that include African-American ethnicity, anti-smooth muscle, anti-
187	DNA, hemolytic anemia, proteinuria, and Raynaud's phenomenon. <sup>3</sup> However, to the best of our
188	knowledge, there have been no studies to date that have investigated the risk factors for
189	recurrence. We found that elevated SLEDAI scores, younger age at disease onset, recurrence

occurring within one year, and higher daily doses of prednisone were independently associated
with a two- to three-fold increased recurrence rate. This suggests that pericarditis recurrence
reflects both patient characteristics and treatment choices. Further, these findings suggest that
specific subgroups of patients with pericarditis may benefit from close monitoring and early
initiation of therapies proven to be effective for recurrent pericarditis, especially as recurrence is
more likely to occur within one year of the onset of pericarditis.<sup>21</sup>

196 The medical management of pericarditis for patients with SLE differs from that for the 197 general population. Although parenteral administration of glucocorticoids may be preferred to 198 prolonged oral administration to mitigate the risk of complications (e.g., avascular necrosis), oral glucocorticoids are still considered for the treatment of SLE flares, including pericarditis.<sup>22,23</sup> In 199 200 contrast, colchicine and non-steroidal anti-inflammatory drugs (NSAIDs) are preferred first-line agents for the treatment of acute pericarditis in the general population.<sup>4,24,25</sup> In fact, the 201 202 Investigation on Colchicine for Acute Pericarditis (ICAP) trial demonstrated that glucocorticoid use is an independent risk factor for recurrence.<sup>25</sup> Furthermore, a meta-analysis of 7 studies, 203 204 which included 471 patients, confirmed these findings: not only did steroids increase the risk of 205 recurrent pericarditis, but low-dose steroids also conferred lower odds of recurrence compared to high-dose steroids (OR 0.29, 95% CI 0.13, 0.66).<sup>26</sup> In the Hopkins Lupus cohort, we observed a 206 207 dose-related effect of oral prednisone treatment on the risk of pericarditis recurrence similar to 208 that in the general population, which was confirmed in the multivariate analysis. This suggests 209 that oral prednisone should be avoided whenever possible in patients with SLE and a history of 210 pericarditis. Further studies will be needed to understand the role of colchicine and IL-1-blocking 211 antibodies in treating recurrent pericarditis in SLE patients.

212	The use of the SLEDAI criteria to diagnose pericarditis is a limitation of this study. The
213	SLEDAI definition of pericarditis is, in fact, less stringent than that used by cardiology
214	associations, such as the European Society of Cardiology (ESC). <sup>18,22</sup> According to the SLEDAI
215	definition, only one of the following criteria is necessary to be present for diagnosis: (1)
216	pericardial pain, (2) auscultation of pericardial rub, (3) presence of pericardial effusion on
217	imaging, and (4) EKG confirmation. <sup>17,18</sup> Within our study cohort, patient-reported pericardial
218	chest pain was used most often to diagnose pericarditis. Importantly, we found that all patients (n
219	= 20) who were further evaluated via modalities, including TTE, CT chest imaging, or EKG,
220	demonstrated findings indicative of pericarditis, thereby fulfilling both SLEDAI and ESC criteria
221	for the diagnosis of pericarditis. This suggests that clinical criteria alone may be a robust tool for
222	diagnosing pericarditis among patients with SLE.
223	To conclude, our study describes the rate of recurrent pericarditis among patients with
224	SLE and describes risk factors associated with recurrence. Our data suggests that, despite the
225	common practice to use prednisone to treat SLE flares, the use of oral corticosteroids should be
226	avoided for those with a recent history of pericarditis. Future studies within this unique
227	population will be needed to determine the most effective treatment method for pericarditis, the
228	most common cardiac complication of systemic lupus erythematosus.

## 230 ACKNOWLEDGMENTS

231	Author contributions: Drs. Luigi Adamo and Andrea Fava had full access to all the data in the
232	study and took responsibility for the integrity of the data and the accuracy of the data analysis.
233	Study concept and design: Luigi Adamo, Andrea Fava, and Michelle Petri. Acquisition, analysis,
234	and interpretation of data: Yoo Jin Kim, Jana Lovell, Alaa Diab, Laurence S. Magder, Daniel
235	Goldman, Michelle Petri, Andrea Fava, and Luigi Adamo. Drafting of the manuscript: Yoo Jin
236	Kim, Jana Lovell, Luigi Adamo, and Andrea Fava. Critical revision of the manuscript for
237	important intellectual content: Yoo Jin Kim, Jana Lovell, Laurence S. Magder, Daniel Goldman,
238	Michelle Petri, Andrea Fava, and Luigi Adamo. Statistical analysis: Laurence S. Magder.
239	
240	Funding/support: This study was supported in part by NHLBI grants 5K08HLO145108-03 and
241	1R01HL160716-01, awarded to Dr. Luigi Adamo, and NHLBI grant T32-HL007227, awarded to
242	Dr. Jana Lovell. The Hopkins Lupus Cohort is supported by R01DK134625, awarded to Dr.
243	Andrea Fava.
244	
245	Financial disclosures: The authors have no financial disclosures immediately relevant to this
246	manuscript to disclose. Dr. Adamo discloses the following other relationships: consultant for
247	Kiniksa Pharmaceutical and co-founder of i-Cordis, LLC, a start-up company focused on
248	developing immunomodulatory small molecules to treat heart failure. All the other authors have
249	no financial interests to report.
250	

#### 251 **REFERENCES**

- 252 1. Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and
- 253 outcome. *Lupus*. 2005;14(10):822-6. doi:10.1191/0961203305lu2187oa
- 254 2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus
- erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort
- 256 of 1,000 patients. *Medicine (Baltimore)*. Sep 2003;82(5):299-308.
- 257 doi:10.1097/01.md.0000091181.93122.55
- 258 3. Ryu S, Fu W, Petri MA. Associates and predictors of pleurisy or pericarditis in SLE.
- 259 *Lupus Sci Med.* 2017;4(1):e000221. doi:10.1136/lupus-2017-000221
- 260 4. Chiabrando JG, Bonaventura A, Vecchie A, et al. Management of Acute and Recurrent
- 261 Pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol. Jan 7 2020;75(1):76-92.
- 262 doi:10.1016/j.jacc.2019.11.021
- 263 5. Caforio AL, Brucato A, Doria A, et al. Anti-heart and anti-intercalated disk
- autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. *Heart*. May
- 265 2010;96(10):779-84. doi:10.1136/hrt.2009.187138
- 266 6. Marcolongo R, Russo R, Laveder F, Noventa F, Agostini C. Immunosuppressive therapy
- 267 prevents recurrent pericarditis. J Am Coll Cardiol. Nov 1 1995;26(5):1276-9. doi:10.1016/0735-

268 1097(95)00302-9

- 269 7. Imazio M, Trinchero R, Shabetai R. Pathogenesis, management, and prevention of
- 270 recurrent pericarditis. J Cardiovasc Med (Hagerstown). Jun 2007;8(6):404-10.
- 271 doi:10.2459/01.JCM.0000269708.72487.34

272 8. Cantarini L, Imazio M, Brizi MG, et al. Role of autoimmunity and autoinflammation in

273 the pathogenesis of idiopathic recurrent pericarditis. *Clin Rev Allergy Immunol*. Feb

274 2013;44(1):6-13. doi:10.1007/s12016-010-8219-x

275 9. Lo Presti S, Elajami TK, Reyaldeen R, Anthony C, Imazio M, Klein AL. Emerging

276 Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors. J Am Heart Assoc. Oct 5

277 2021;10(19):e021685. doi:10.1161/JAHA.121.021685

278 10. Klein AL, Imazio M, Cremer P, et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in

279 Recurrent Pericarditis. N Engl J Med. Jan 7 2021;384(1):31-41. doi:10.1056/NEJMoa2027892

280 11. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary

results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with

282 severe lupus arthritis. Ann Rheum Dis. Apr 2005;64(4):630-3. doi:10.1136/ard.2004.025858

283 12. Cacoub P, Marques C. Acute recurrent pericarditis: from pathophysiology towards new

284 treatment strategy. *Heart*. Jul 2020;106(14):1046-1051. doi:10.1136/heartjnl-2019-316481

285 13. Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis

286 Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP

287 Randomized Clinical Trial. *JAMA*. Nov 8 2016;316(18):1906-1912.

288 doi:10.1001/jama.2016.15826

289 14. Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of Idiopathic

290 Recurrent Pericarditis With Goflikicept: Phase II/III Study Results. J Am Coll Cardiol. Jul 4

291 2023;82(1):30-40. doi:10.1016/j.jacc.2023.04.046

292 15. Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep. Sep

293 2013;15(9):360. doi:10.1007/s11926-013-0360-0

- 16. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the
- 295 Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage
- index for systemic lupus erythematosus. *Arthritis Rheum*. Mar 1996;39(3):363-9.
- 297 doi:10.1002/art.1780390303
- 298 17. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with
- systemic lupus erythematosus. *N Engl J Med.* Dec 15 2005;353(24):2550-8.
- 300 doi:10.1056/NEJMoa051135
- 301 18. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and
- 302 management of pericardial diseases: The Task Force for the Diagnosis and Management of
- 303 Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European
- 304 Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* Nov 7 2015;36(42):2921-2964.
- doi:10.1093/eurheartj/ehv318
- 306 19. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation
- 307 of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart
- 308 Study. *Stat Med.* Dec 1990;9(12):1501-15. doi:10.1002/sim.4780091214
- 309 20. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J
- 310 Autoimmun. Jan 2019;96:1-13. doi:10.1016/j.jaut.2018.11.001
- 311 21. Fava A, Cammarata M, Adamo L. Rilonacept use in lupus pericarditis. *Clin Exp*
- 312 *Rheumatol.* Mar 19 2024;doi:10.55563/clinexprheumatol/pb3hzb
- 313 22. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the
- 314 management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. Jan 2
- 315 2024;83(1):15-29. doi:10.1136/ard-2023-224762

316	23.	Kallas R, Li J, Petri M. Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A
317	Prospe	ective Cohort Study. Arthritis Care Res (Hoboken). Jul 2022;74(7):1122-1132.
318	doi:10	.1002/acr.24541
319	24.	Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of
320	multip	le recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled,
321	randor	nised trial. Lancet. Jun 28 2014;383(9936):2232-7. doi:10.1016/S0140-6736(13)62709-9
322	25.	Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute
323	perica	rditis. N Engl J Med. Oct 17 2013;369(16):1522-8. doi:10.1056/NEJMoa1208536
324	26.	Lotrionte M, Biondi-Zoccai G, Imazio M, et al. International collaborative systematic
325	review	of controlled clinical trials on pharmacologic treatments for acute pericarditis and its
326	recurre	ences. Am Heart J. Oct 2010;160(4):662-70. doi:10.1016/j.ahj.2010.06.015
327		
328		
329		
330		
331		

## 332 TABLES AND FIGURES

	<b>All</b> (N = 590)
Age at first episode of pericarditis (years), no. (%)	
< 30	257 (44)
30-44	208 (35)
45-59	102 (17)
≥ 60	23 (4)
Female sex, no. (%)	535 (91)
Race, no. (%)	
White	253 (43)
Black	303 (51)
Other	34 (6)
Onset of pericarditis, no. (%)	
< 1990	106 (18)
1990 – 1999	165 (28)
2000 – 2009	215 (36)
≥ 2010	104 (18)
Duration of follow-up after onset of pericarditis (person-years), no. (%)	
< 5	260 (44)
5 – 10	115 (19)
10 – 15	91 (15)
15 – 20	55 (9)
≥ 20	69 (12)
Recurrent episodes of pericarditis, no. (%)	. ,
1	61 (10)
2 – 4	46 (8)
5 – 12	13 (2)

## Table 1. Demographics and Clinical Characteristics of Patientswith Pericarditis in the Hopkins Lupus Cohort

Table 2. Rates of recurrent pericarditis by demographic, clinical, and treatment characteristics

Exposure	Events, no.	Rate, per person-years	Rate ratio (95% CI)	<i>P</i> -value
Demographic characteristics		person-years		i -valuc
Age group, years				
18-39*	171	0.085	1.0 (Ref)	NA
40-49	74	0.054	0.58 (0.37,0.90)	0.016
50-59	28	0.025	0.25 (0.12,0.53)	<.001
≥60	5	0.006	0.05 (0.01,0.18)	<.001
Sex				
Female*	260	0.054	1.0 (Ref)	NA
Male	18	0.038	0.43 (0.11,1.69)	0.228
Race medRxiv preprint doi: https://doi.org/10.1	101/2024.06.09.2430	8628: this version poste	ed June 10. 2024. The copyrigh	ht holder for thi
White(which was not certified by peer review				reprinNAperpe
Black	172		<sup>t permission</sup> 1.72 (0.99,2.97)	0.054
Other	9	0.032	0.90 (0.34,2.34)	0.827
Year of onset of pericarditis				
Before 2000*	71	0.082	1.0 (Ref)	NA
2000 – 2009	98	0.055	0.59 (0.39,0.89)	0.011
After 2010	109	0.042	0.36 (0.22,0.61)	<.001
Clinical characteristics				
Time from initial episode				
<1*	48	0.212	1.0 (Ref)	NA
1-3	59	0.105	0.50 (0.32,0.79)	0.003
3-10	91	0.048	0.21 (0.14,0.32)	<.001
≥10	80	0.031	0.12 (0.06,0.23)	<.001
Most recent past clinical findings				
Disease activity, SLEDAI				
0*	52	0.032	1.0 (Ref)	NA
1-2	58	0.043	1.32 (0.92,1.89)	0.130
≥10	156	0.088	2.34 (1.65,3.30)	<.001
Low C3	187	0.051	0.76 (0.52,1.09)	0.139
Normal*	79	0.075	1.0 (Ref)	NA
∟ow C4	190	0.048	0.54 (0.37,0.78)	0.001
Normal*	75	0.098	1.0 (Ref)	NA
Anti-dsDNA seropositive	138	0.088	2.05 (1.40,2.99)	<.001
Seronegative*	127	0.041	1.0 (Ref)	NA
History of various conditions				
Anti-SM seropositive	198	0.053	1.06 (0.65,1.72)	0.819
Seronegative*	75	0.049	1.0 (Ref)	NA
Proteinuria	123	0.041	0.58 (0.37,0.89)	0.013
No history*	146	0.069	1.0 (Ref)	NA
Nephrotic syndrome	34	0.028	0.47 (0.27,0.82)	0.008
No history*	242	0.06	1.0 (Ref)	NA
Pulmonary fibrosis	50	0.063	1.29 (0.55,3.02)	0.563
No history*	227	0.051	1.0 (Ref)	NA
Pulmonary hypertension	26	0.028	0.42 (0.19,0.92)	0.030
No history*	252	0.058	1.0 (Ref)	NA
Hemolytic anemia	33	0.038	0.76 (0.44,1.30)	0.321
No history*	242	0.055	1.0 (Ref)	NA
_ymphadenopathy	107	0.047	0.70 (0.37,1.34)	0.283
No history*	158	0.053	1.0 (Ref)	NA 0.077
Raynaud syndrome	131	0.04	0.53 (0.27,1.07)	0.077
Not present*	146	0.074	1.0 (Ref)	NA
urrent Treatment characteristics				
Prednisone, mg/day	00	0.045		N I A
0*	98	0.045	1.0 (Ref)	NA
1-9	79	0.052	1.54 (0.85,2.79)	0.154
10-19	45	0.076	2.23 (1.25,4.00)	0.007
≥20	216	0.063	3.92 (2.31,6.63)	<.001
Hydroxychloroquine use	62	0.046	1.04 (0.70,1.53)	0.854
Not present*	112	0.058	1.0 (Ref)	NA
Immunosuppressant use	166	0.059	0.92 (0.62,1.36)	0.678

\* Reference rate for determination of rate ratio for the recurrence of pericarditis

- **Figure 1.** Results of multivariate analyses demonstrating predictors of recurrent pericarditis
- among patients with SLE. Reference rates for the determination rate ratios are summarized in
- 336 <u>Table 2</u>.

# **Predictors of recurrent pericarditis**

